# US 2015/0064210 A1 · Humoral immune response against tumor antigens after treatment with a cancer antigen specific active immunotherapy and its association with improved clinical outcome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0064210 A1
- Document ID: US20150064210A1
- Status: Published application
- Kind: A1
- Application number: 14/479,084
- Filed: 2014-09-05
- Published: 2015-03-05
- Earliest claimed: 2013-09-05
- Assignees: Dendreon Corporation
- Applicants: Dendreon Corporation
- Inventors: Debraj GuhaThakurta; James Trager; Nadeem Sheikh
- Web page: https://patentgrep.com/patent/US20150064210A1

## CPC

- G01N 33/6854: {Immunoglobulins}
- A61K 40/10: characterised by the cell type used
- A61K 40/4274: {Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; Prostatic acid phosphatase [PAP]; Prostate-specific G-protein-coupled receptor [PSGR]}
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/57555: of the prostate
- A61K 2039/575: {humoral response}
- G01N 2500/00: Screening for compounds of potential therapeutic value
- G01N 2800/52: Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
- G16H 50/50: for simulation or modelling of medical disorders
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers.

## Claims

### Claim 1

A method of determining a cancer patient's therapeutic response to cancer antigen specific active immunotherapy (CASAI) treatment with a target cancer antigen, the method comprising the steps of:
i. obtaining a baseline antibody level reactive to one or more non-target predetermined biomarker antigens;
ii. treating the cancer patient with CASAI using the target cancer antigen;
iii. obtaining a post-treatment antibody level reactive to the one or more non-target predetermined biomarker antigens from a patient blood sample after treating with CASAI; and,
iv. measuring differences between the baseline and post-treatment antibody levels reactive to the one or more non-target predetermined biomarker antigens,
where an increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 2 (depends on 1)

The method of claim 1, wherein the method further comprises:
v. obtaining a baseline and a post-treatment antibody level reactive to the target cancer antigen; and
vi. measuring the difference between the baseline and the post-treatment antibody levels reactive to the target cancer antigen,
wherein an increase in the antibody level reactive to the target cancer antigen and the increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 3 (depends on 2)

The method of claim 2, wherein the increase in the antibody level reactive to the target cancer antigen and the increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline levels is more predictive of a positive therapeutic response in comparison to the increase of the antibody level reactive to the target cancer antigen alone.

### Claim 4 (depends on 1)

The method of claim 1, wherein a baseline and a post-treatment reactive antibody level to at least two non-target predetermined biomarker antigens are determined.

### Claim 5 (depends on 1)

The method of claim 1, wherein the baseline reactive antibody levels or the post-treatment reactive antibody levels from the patient are reactive IgG levels.

### Claim 6 (depends on 1)

The method of claim 1 wherein the CASAI treatment includes the step of activating patient blood cells under ex vivo conditions.

### Claim 7 (depends on 1)

The method of claim 1 wherein the CASAI treatment uses a target cancer antigen selected from the group consisting of prostatic acid phosphatase (PAP) and a PAP fusion protein.

### Claim 8 (depends on 1)

The method of claim 1 wherein the CASAI treatment uses a PAP-GM-CSF as a target cancer antigen.

### Claim 9 (depends on 1)

The method of claim 1 wherein the patient suffers from a cancer selected from the group consisting of prostate cancer, melanoma, glioma, bladder cancer, urothelial cancer, kidney cancer, lung cancer, breast cancer, liver cancer, pancreatic cancer and colorectal cancer.

### Claim 10 (depends on 1)

The method of claim 1 wherein the patient suffers from prostate cancer.

### Claim 11 (depends on 1)

The method of claim 1 wherein the reactive antibody levels are measured using a solid support surface and a fluorescent or enzymatic label.

### Claim 12 (depends on 1)

The method of claim 1 wherein CASAI uses an immunomodulator.

### Claim 13 (depends on 12)

The method of claim 12 wherein CASAI uses an immunomodulator selected from the group consisting of GM-CSF, an agonists of toll-like receptor (TLR)-2, 3, 4, 5, 7, 8 or 9; a checkpoint inhibitor; a cytokine; and an inhibitor of interleukin (IL)-12, IL-12p70, IL-10, IL-35, transforming growth factor (TGF)β, or indolamine-pyrrole-2,3-dioxygenase (IDO).

### Claim 14 (depends on 13)

The method of claim 13, wherein the cytokine is selected from the group consisting of IL-1, IL-2, IL-4, IL-7, IL-12, IL-15, and IL-21.

### Claim 15 (depends on 13)

The method of claim 13, wherein the inhibitor of IL-12, IL-12p70, IL-10, IL-35, TGFβ, or IDO is an antibody that binds to IL-12, IL-12p70, IL-10, IL-35, TGFβ, or IDO.

### Claim 16 (depends on 1)

The method of claim 1 wherein the one or more non-target predetermined biomarker antigens are PSA and one or more other non-target predetermined biomarker antigens.

### Claim 17 (depends on 16)

The method of claim 16 wherein the one or more non-target predetermined biomarker antigens are PSA and one or more of KLK2, KRAS, ERAS, LGALS8, or LGALS3.

### Claim 18 (depends on 1)

The method of claim 1 wherein the target cancer antigen is not PSA and the non-target predetermined biomarker antigen is PSA.

### Claim 19 (depends on 1)

The method of claim 1 wherein the non-target predetermined biomarker antigens include ERAS plus any 4 markers selected from the group consisting of KLK2, KRAS, LGALS8, LGALS3, and PSA.

### Claim 20 (depends on 1)

The method of claim 1 wherein the non-target predetermined biomarker antigens include KRAS plus any 4 markers selected from the group consisting of KLK2, ERAS, LGALS8, LGALS3, and PSA.

### Claim 21 (depends on 1)

The method of claim 1 wherein the non-target predetermined biomarker antigens include ERAS.

### Claim 22 (depends on 1)

The method of claim 1 wherein the non-target predetermined biomarker antigens include KLK2.

### Claim 23 (depends on 1)

The method of claim 1 wherein the non-target predetermined biomarker antigens include PSA.

### Claim 24

A method of determining therapeutic response in prostate cancer patients undergoing sipuleucel-T treatment, the method comprising the steps of:
i. obtaining a baseline level of antibody reactive to one or more non-target predetermined biomarker antigens, said non-target predetermined biomarker antigens selected from the group consisting of PSA, KLK2, KRAS, ERAS, LGALS8, and LGALS3;
ii. administering to the cancer patient T cells activated ex vivo using a protein comprising a PAP amino acid sequence;
iii. obtaining a post-treatment antibody level reactive to the one or more non-target predetermined biomarker antigens from a patient blood sample after treating with the activated T cells; and,
iv. measuring differences between the baseline and post-treatment reactive antibody levels to the one or more non-target predetermined biomarker antigens where an increase in antibody level for the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 25 (depends on 24)

The method of claim 24, wherein the method further comprises:
v. obtaining a baseline and a post-treatment antibody level reactive to the target cancer antigen; and
vi. measuring the difference between the baseline and the post-treatment antibody levels reactive to the target cancer antigen,
wherein an increase in the antibody level reactive to the target cancer antigen and the increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 26 (depends on 24)

The method of claim 24, wherein the increase in the antibody level reactive to the target cancer antigen and the increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline levels is more predictive of a positive therapeutic response in comparison to the increase of the antibody level reactive to the target cancer antigen alone.

### Claim 27 (depends on 24)

The method of claim 24, wherein the protein comprising the PAP amino acid sequence is a PAP-GM-CSF fusion protein.

### Claim 28 (depends on 24)

The method of claim 24, wherein the baseline reactive antibody levels or the post-treatment reactive antibody levels from the patient are reactive IgG levels.

### Claim 29 (depends on 24)

The method of claim 24, wherein the sipuleucel-T treatment is ex vivo.

### Claim 30 (depends on 24)

The method of claim 24, wherein the reactive antibody levels are measured using a solid support surface and a fluorescent or enzymatic label.

### Claim 31 (depends on 24)

The method of claim 24, wherein one of the non-target predetermined biomarker antigens is ERAS.

### Claim 32 (depends on 24)

The method of claim 24, wherein one of the non-target predetermined biomarker antigens is KLK2.

### Claim 33 (depends on 24)

The method of claim 24, wherein one of the non-target predetermined biomarker antigens is PSA.

### Claim 34

A method of identifying target antigens for cancer treatment with improved patient survival, the method comprising:
i. obtaining baseline level of antibody reactive to one or more non-target predetermined biomarker antigens;
ii. treating a patient suffering from cancer with cancer immunotherapy;
iii. obtaining a post-treatment level of antibody reactive to the one or more non-target predetermined biomarker antigens from a patient blood sample after treating with the cancer immunotherapy;
iv. comparing the baseline and post-treatment reactive antibody levels to determine one or more non-target predetermined biomarker antigens in which the reactive antibody level is increased;
v. correlating the increase in the one or more non-target predetermined biomarker antigen reactive antibody levels to an increase in survival; and
vi. identifying the one or more non-target predetermined biomarker antigens in which the increase in reactive antibody levels are correlated with survival as target antigens for cancer treatment with improved patient survival.

### Claim 35

A system for determining a cancer patient's therapeutic response to cancer antigen specific active immunotherapy (CASAI) treatment with a target cancer antigen, the system comprising:
i. a processor;
ii. a memory coupled with the processor via an interconnect;
iii. a communications interface coupled with the interconnect and adapted to:
a. receive a first set of electronic data signals representing a set of pre-treatment interrelated values, each value indicative of a baseline antibody level reactive to one or more non-target predetermined biomarker antigens before CASAI treatment;
b. receive a second set of electronic data signals representing a set of post-treatment interrelated values corresponding to the set of pre-treatment values, each of the second set of values indicating an antibody level reactive to the one or more non-target predetermined biomarker antigens from a patient blood sample after treating with CASAI;
iv. a comparison engine coupled with the processor and configured to compare the set of pre-treatment values with the set of post-treatment values to determine which of the set of post-treatment values have changed from the set of pre-treatment values; and
v. an output module configured to provide output data signals representing which of the set of post-treatment values have changed from the set of pre-treatment values, wherein an increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 36 (depends on 35)

The system of claim 35, wherein the processor is further configured to determine a reference set of values to serve as a baseline antibody level for the patient from the set of pre-treatment values indicative of a baseline antibody level reactive to one or more non-target predetermined biomarker antigens before CASAI treatment.

### Claim 37 (depends on 35)

The system of claim 35, wherein the one or more non-target predetermined biomarker antigens are selected from the group consisting of PSA, KLK2, KRAS, ERAS, LGALS8, and LGALS3.

### Claim 38 (depends on 37)

The system of claim 37, wherein the target cancer antigen used in CASAI treatment is not PSA and the one or more non-target predetermined biomarker antigens comprise PSA.

### Claim 39 (depends on 37)

The system of claim 37, wherein the target cancer antigen used in CASAI treatment is PSA and the one or more non-target predetermined biomarker antigens do not comprise PSA.

### Claim 40 (depends on 35)

The system of claim 35, wherein the reactive antibody levels are reactive IgG levels.

### Claim 41 (depends on 35)

The system of claim 35, wherein the target cancer antigen is PAP or a PAP fusion protein.

### Claim 42 (depends on 35)

The system of claim 35, wherein the
iii. communications interface is further adapted to receive a set of electronic data signals representing a pre-treatment and a post-treatment interrelated value, the pre-treatment value indicative of a baseline antibody level reactive to the target cancer antigen before CASAI treatment, and the post-treatment value indicative of an antibody level reactive to the target cancer antigen after treating with CASAI;
iv. comparison engine is further configured to compare the set of pre- and post-treatment values of antibody levels reactive to the target cancer antigen to determine whether the post-treatment value of antibody level reactive to the target cancer antigen has changed from the pre-treatment value; and
v. output module is further configured to provide an output data signal representing whether the post-treatment value of antibody level reactive to the target cancer antigen has changed from the pre-treatment value, wherein:
an increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level; and
an increase in the antibody level reactive to the one or more non-target predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.

### Claim 43

A method of determining therapeutic response in prostate cancer patients undergoing immunomodulatory treatment, the method comprising the steps of:
i. obtaining a baseline level of antibody reactive to one or more predetermined biomarker antigens, said predetermined biomarker antigens selected from the group consisting of PSA, KLK2, KRAS, ERAS, LGALS8, and LGALS3;
ii. administering to the prostate cancer patient an immunomodulatory agent;
iii. obtaining a post-treatment level of antibody reactive to one or more predetermined biomarker antigens from a patient blood sample after treating with the immunomodulatory agent, said predetermined biomarker antigens selected from the group consisting of PSA, KLK2, KRAS, ERAS, LGALS8, and LGALS3; and
iv. comparing differences between the baseline and post-treatment reactive antibody levels to the one or more predetermined biomarker antigens,
wherein an increase in antibody level for the predetermined biomarker antigens over their baseline level predicts a positive therapeutic response.
